Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Altered reward processing in the orbitofrontal cortex and hippocampus in healthy first-degree relatives of patients with depression.

Macoveanu J, Knorr U, Skimminge A, Søndergaard MG, Jørgensen A, Fauerholdt-Jepsen M, Paulson OB, Knudsen GM, Siebner HR, Kessing LV.

Psychol Med. 2014 Apr;44(6):1183-95. doi: 10.1017/S0033291713001815. Epub 2013 Jul 19.

PMID:
23866315
3.

Effects of selective serotonin reuptake inhibition on neural activity related to risky decisions and monetary rewards in healthy males.

Macoveanu J, Fisher PM, Haahr ME, Frokjaer VG, Knudsen GM, Siebner HR.

Neuroimage. 2014 Oct 1;99:434-42. doi: 10.1016/j.neuroimage.2014.05.040. Epub 2014 May 22.

PMID:
24857827
4.

Playing it safe but losing anyway--serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion.

Macoveanu J, Rowe JB, Hornboll B, Elliott R, Paulson OB, Knudsen GM, Siebner HR.

Eur Neuropsychopharmacol. 2013 Aug;23(8):919-30. doi: 10.1016/j.euroneuro.2012.09.006. Epub 2012 Oct 7.

5.

Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.

McCabe C, Mishor Z, Cowen PJ, Harmer CJ.

Biol Psychiatry. 2010 Mar 1;67(5):439-45. doi: 10.1016/j.biopsych.2009.11.001. Epub 2009 Dec 24.

6.

Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: a randomized trial.

Knorr U, Vinberg M, Mortensen EL, Winkel P, Gluud C, Wetterslev J, Gether U, Kessing LV.

PLoS One. 2012;7(2):e31980. doi: 10.1371/journal.pone.0031980. Epub 2012 Feb 29.

7.

Neurobiology of decision making in depressed adolescents: a functional magnetic resonance imaging study.

Shad MU, Bidesi AP, Chen LA, Ernst M, Rao U.

J Am Acad Child Adolesc Psychiatry. 2011 Jun;50(6):612-621.e2. doi: 10.1016/j.jaac.2011.03.011. Epub 2011 Apr 29.

8.

Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.

Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U, Gerstl F, Fink M, Moser E, Kasper S.

Neuroimage. 2010 Jan 15;49(2):1161-70. doi: 10.1016/j.neuroimage.2009.10.013. Epub 2009 Oct 13.

PMID:
19833214
9.

Gray matter volume and rapid decision-making in major depressive disorder.

Nakano M, Matsuo K, Nakashima M, Matsubara T, Harada K, Egashira K, Masaki H, Takahashi K, Watanabe Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:51-6. doi: 10.1016/j.pnpbp.2013.09.011. Epub 2013 Sep 25.

PMID:
24076064
10.

Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.

Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ.

Psychol Med. 2012 Dec;42(12):2609-17. doi: 10.1017/S0033291712000591. Epub 2012 Apr 25.

11.

Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe.

Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, Busto UE.

Arch Gen Psychiatry. 2005 Nov;62(11):1228-36.

PMID:
16275810
12.

Escitalopram and neuroendocrine response in healthy first-degree relatives to depressed patients--a randomized placebo-controlled trial.

Knorr U, Vinberg M, Hansen A, Klose M, Feldt-Rasmussen U, Hilsted L, Hasselstrøm J, Gether U, Winkel P, Gluud C, Wetterslev J, Kessing LV.

PLoS One. 2011;6(6):e21224. doi: 10.1371/journal.pone.0021224. Epub 2011 Jun 27.

13.

fMRI response to negative words and SSRI treatment outcome in major depressive disorder: a preliminary study.

Miller JM, Schneck N, Siegle GJ, Chen Y, Ogden RT, Kikuchi T, Oquendo MA, Mann JJ, Parsey RV.

Psychiatry Res. 2013 Dec 30;214(3):296-305. Erratum in: Psychiatry Res. 2014 Jun 30;222(3):173-5.

14.

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Burke WJ, Gergel I, Bose A.

J Clin Psychiatry. 2002 Apr;63(4):331-6.

PMID:
12000207
15.

The role of 5-HT in response inhibition and re-engagement.

Drueke B, Schlaegel SM, Seifert A, Moeller O, Gründer G, Gauggel S, Boecker M.

Eur Neuropsychopharmacol. 2013 Aug;23(8):830-41. doi: 10.1016/j.euroneuro.2013.05.005. Epub 2013 Jun 29.

PMID:
23816061
16.

Escitalopram effects on insula and amygdala BOLD activation during emotional processing.

Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP.

Psychopharmacology (Berl). 2008 Mar;196(4):661-72. Epub 2007 Dec 6.

17.

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

Wade A, Michael Lemming O, Bang Hedegaard K.

Int Clin Psychopharmacol. 2002 May;17(3):95-102.

PMID:
11981349
18.

Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder.

Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD, Iosifescu DV, Rauch SL, Fava M.

Am J Psychiatry. 2009 Jun;166(6):702-10. doi: 10.1176/appi.ajp.2008.08081201. Epub 2009 May 1.

19.

Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs.

Abler B, Grön G, Hartmann A, Metzger C, Walter M.

J Neurosci. 2012 Jan 25;32(4):1329-35. doi: 10.1523/JNEUROSCI.5826-11.2012.

20.

Short-term effects of escitalopram on regional brain function in first-episode drug-naive patients with major depressive disorder assessed by resting-state functional magnetic resonance imaging.

Wang L, Li K, Zhang Q, Zeng Y, Dai W, Su Y, Wang G, Tan Y, Jin Z, Yu X, Si T.

Psychol Med. 2014 May;44(7):1417-26. doi: 10.1017/S0033291713002031. Epub 2013 Aug 13.

PMID:
23942213
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk